An interventional study of Dual-energy X-ray absorptiometry in Sarcopenia, sponsored by Centre Hospitalier Régional d'Orléans. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Centre Hospitalier Régional d'Orléans · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Sarcopenia with a site in France — 23 open to participants now, 24 under way, none of them phase 3. Sarcopenia · France.
Among the 78 studies in Sarcopenia with a site in France, this one is the 7th largest by planned enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2023, is one of 49 with no phase, reaches primary completion later than 10 of the 23 other live ones, and was the 58th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →23 of the 78 studies in Sarcopenia with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 75+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 65+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 75+
Hospices Civils de Lyon · Sites in France
Ages 18–74
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 298 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 98 across the 53 interventional studies, 72 across the 25 observational. Of the 38 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 78 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Régional d'Orléans is the lead sponsor of 132 studies on the registry; 32 are open to participants now.
Centre Hospitalier Régional d'Orléans has 3 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
9 of the studies in Sarcopenia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05228262University Hospital, Clermont-FerrandVascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis | 2027-02-01 |
| NCT05488093University Hospital, MontpellierEvaluation of Mobility in Subjects With Severe Knee Osteoarthritis Who Are to Undergo Total Knee Replacement | 2027-03 |
| NCT06963359Assistance Publique - Hôpitaux de ParisHigh-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia | 2027-03 |
| NCT05869487Centre Hospitalier Régional d'OrléansCalf Circumference Versus X-ray Absorptiometry in the Diagnosis of Sarcopenia in Elderly Hospitalized Patients | 2027-04-11 |
| NCT07864857University Hospital, GrenobleAutomated and Reliable Estimation of Patient Height From CT Scan Using an Artificial Intelligence Algorithm | 2027-04-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 78 studies in Sarcopenia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective single-center study to evaluate a diagnostic method. The main objective of the study is to evaluate the performance of calf circumference as a diagnostic method for sarcopenia in hospitalized elderly people, compared to a gold standard method which is X-ray absorptiometry. The study population are hospitalizing participants aged 75 years and older with an indication to search for sarcopenia.
Sarcopenia is a loss of muscle mass associated with a loss of muscle strength. Sarcopenia is associated with an increase of mortality, risk of falling and hospitalization. The gold standard for assessing loss of muscle mass is X-ray absorptiometry. However, this exam is not systematically performed. The calf circumference (cutoff less than 31 centimeters) is preferentially used. However, this cutoff was defined from a population of women with a mean age of 80 years and a unfrail phenotypic profile that does not allow this result to be applied to elderly hospitalized patients.
The main objective of this study is to evaluate the performance of calf circumference as a diagnostic method for sarcopenia in hospitalized elderly people, compared to a gold standard method which is X-ray absorptiometry.
This is a single-center prospective study to evaluate a diagnostic method. The participants in the study will be hospitalized patients aged 75 years and over, with an indication to search for sarcopenia in the context of screening for protein-energy undernutrition under the recommendations of the French National Authority for Health. Participants will be included after being informed about the protocol and after obtaining their free and informed oral consent. Measurement of calf circumference will be performed before absorptiometry, the results of which will be analyzed in a blinded. The number of subjects to be included with a expected prevalence of 75%, specificity of 95% and an accuracy of 2% is 298 participants according to the literature. A sensitivity and specificity analysis will be performed using the ROC curve. A linear regression analysis will be performed with a significance threshold for the alpha risk of 5%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Whole body x-ray absorptiometry for measurement of appendicular muscle mass in kilograms. Only one measurement per participant.
Radiation: Dual-energy X-ray absorptiometry
Whole body x-ray absorptiometry
Measurement of muscle mass using calf circumference
Measurement with a tape measure (in centimetres) of the maximum circumference of the calf
Time frame: Day 2
Measurement of muscle mass using X-ray absorptiometry
Measurement of appendicular mass by X-ray absorptiometry in kilograms
Time frame: Day 2
Arm circumference
Measurement with a tape measure (in centimetres) of the maximum circumference of the arm
Time frame: Day 0
Circumference of the thigh
Measurement with a tape measure (in centimetres) of the maximum circumference of the thigh
Time frame: Day 0
Plan to share: No
Started Dec 2023 (actual). Primary completion is estimated for Apr 2027, 40 months after the start.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 40 months is above that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Régional d'Orléans →